Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Details) - USD ($)	3 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 124,564	$ 144,146
Employee and director stock option grants [Member] \| Research and development [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	29,395	23,735
Employee and director stock option grants [Member] \| General and administrative [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 95,169	$ 120,411